Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case

We recently reported the safety, immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patients with advanced hepatocellular carcinoma (HCC). We conducted a subsequent trial in advanced HCC to assess the histopathological findings before and after vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Yu, Yoshikawa, Toshiaki, Fujii, Satoshi, Mitsunaga, Shuichi, Nobuoka, Daisuke, Mizuno, Shoichi, Takahashi, Mari, Yamauchi, Chisako, Endo, Itaru, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901810/
https://www.ncbi.nlm.nih.gov/pubmed/23466818
http://dx.doi.org/10.4161/hv.24179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901810/
https://www.ncbi.nlm.nih.gov/pubmed/23466818
http://dx.doi.org/10.4161/hv.24179

Ejemplares similares